AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16130059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine anesthesia (IV ketamine 1 to 2 mg/kg, fentanyl 1 to 2 microg/kg, maintained with ketamine 25 to 75 microg/kg/min and fentanyl 10 microg/kg/h)
Number of subjects: 34
Study 16130059 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia (IV thiopental sodium 3 to 5 mg/kg, fentanyl 1 to 2 microg/kg, maintained with 1% isoflurane and fentanyl 10 microg/kg/h)
Number of subjects: 34
Study 12153124 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments about the Latina woman
Number of subjects: 0
Study 12153124 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments about the Anglo-Saxon and Jewish women
Number of subjects: 0
Study 10487074 — intervention group
Group type: EXPERIMENTAL
Intervention: RGP contact lenses worn for about 8 hours a day
Number of subjects: 100
Study 10487074 — intervention group
Group type: EXPERIMENTAL
Intervention: RGP contact lenses
Number of subjects: 100
Study 10487074 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 100
Study 8757425 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 1,000 mg alone
Number of subjects: 40
Study 8757425 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 500 mg + low-dose interferon-alpha (IFN-alpha 3 MIU three times weekly)
Number of subjects: 40
Study 1888646 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional carbamazepine (CBZ)
Number of subjects: 21
Study 1888646 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release carbamazepine (CBZ-CR)
Number of subjects: 21
Study 7114833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibekacin
Number of subjects: 0
Study 7114833 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 0
Study 30703349 — intervention group
Group type: COMPARATOR
Intervention: Epidural steroid injection (ESI) and education only
Number of subjects: 54
Study 30703349 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection plus physical therapy (ESI+PT)
Number of subjects: 54
Study 29532649 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 0
Study 29532649 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal vibration
Number of subjects: 0
Study 26460229 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-weeks group (discontinuation of risperidone or olanzapine at 24 weeks)
Number of subjects: 159
Study 26460229 — intervention group
Group type: EXPERIMENTAL
Intervention: 52-weeks group (continuation of risperidone or olanzapine for the full duration of the study)
Number of subjects: 159
Study 26460229 — intervention group
Group type: EXPERIMENTAL
Intervention: 52-weeks group
Number of subjects: 159
Study 26460229 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine patients in the 52-weeks group
Number of subjects: 159
Study 26460229 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone patients in the 52-weeks group
Number of subjects: 159
Study 26460229 — intervention group
Group type: COMPARATOR
Intervention: 0-weeks group
Number of subjects: 159
Study 26460229 — intervention group
Group type: COMPARATOR
Intervention: 24-weeks group
Number of subjects: 159
Study 24436491 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal-specific oral nutrition supplement (RS-ONS)
Number of subjects: 62
Study 24436491 — intervention group
Group type: COMPARATOR
Intervention: Standard recommended nutrition regime (CON)
Number of subjects: 62
Study 22952598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 8 g/d (1.6 g/d EPA+DHA)
Number of subjects: 33
Study 22952598 — intervention group
Group type: COMPARATOR
Intervention: High oleic sunflower oil (HOSO) 8 g/d
Number of subjects: 33
Study 19544043 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinting plus low-level laser therapy (SLLLT)
Number of subjects: 45
Study 19544043 — intervention group
Group type: COMPARATOR
Intervention: Splinting (S)
Number of subjects: 45
Study 17894323 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based dosing of ribavirin (RBV)
Number of subjects: 362
Study 17894323 — intervention group
Group type: COMPARATOR
Intervention: Flat dosing of ribavirin (RBV)
Number of subjects: 362
Study 14716191 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 95
Study 14716191 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 95
Study 14716191 — intervention group
Group type: COMPARATOR
Intervention: Hormone Therapy (HT)
Number of subjects: 95
Study 14716191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 11132612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25-200 mg)
Number of subjects: 667
Study 11132612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 9113185 — intervention group
Group type: EXPERIMENTAL
Intervention: ALAGLN-group (alanyl-glutamine solution)
Number of subjects: 19
Study 9113185 — intervention group
Group type: COMPARATOR
Intervention: AA-group (glucose and balanced amino acid solution)
Number of subjects: 19
Study 9113185 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 8469622 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg
Number of subjects: 11
Study 8469622 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg
Number of subjects: 11
Study 8469622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3951003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (CX)
Number of subjects: 195
Study 3951003 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin/Gentamicin (CG)
Number of subjects: 195
Study 3277830 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated gestational diabetes (group II)
Number of subjects: 141
Study 3277830 — intervention group
Group type: COMPARATOR
Intervention: Unsatisfactorily treated gestational diabetes (group III)
Number of subjects: 141
Study 31179791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 31179791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30472919 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation group (motivation experimentally induced after the fatigue protocol)
Number of subjects: 60
Study 30472919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no motivation induced after the fatigue protocol)
Number of subjects: 60
Study 27474536 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL exposure at 22, 34, 46 J/cm2 or triple stacking of 46 J/cm2
Number of subjects: 15
Study 27474536 — intervention group
Group type: COMPARATOR
Intervention: Single solar‐simulated UVR exposure of 3 Standard Erythema Dose at 30 minutes or 24 hours after IPL
Number of subjects: 15
Study 27474536 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology (H&E, Fontana‐Masson)
Number of subjects: 15
Study 27474536 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-expression of p53
Number of subjects: 15
Study 25499673 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreaching stepped care program (Lust for Life)
Number of subjects: 263
Study 25499673 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 263
Study 23442339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail (MICRONAILTM)
Number of subjects: 62
Study 23442339 — intervention group
Group type: COMPARATOR
Intervention: Volar locking plate
Number of subjects: 62
Study 21988742 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (200 U/kg intravenously)
Number of subjects: 0
Study 21988742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 0
Study 18317951 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium treatment
Number of subjects: 167
Study 18317951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 167
Study 16503705 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise methadone induction (28, 56, then 84 mg/day)
Number of subjects: 34
Study 16503705 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid methadone induction (28-84 mg on Days 1-6 to 56 mg/day)
Number of subjects: 34
Study 16503705 — intervention group
Group type: COMPARATOR
Intervention: Both groups (common contingency-management intervention)
Number of subjects: 34
Study 12905979 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (PPI + bismuth-based triple therapy)
Number of subjects: 3
Study 12905979 — intervention group
Group type: COMPARATOR
Intervention: PPI-based triple therapy
Number of subjects: 3
Study 12905979 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 3
Study 11151436 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imaging (GI) relaxation techniques
Number of subjects: 86
Study 11151436 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 86
Study 9371898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 20 mg
Number of subjects: 845
Study 9371898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 10 mg
Number of subjects: 845
Study 9371898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 845
Study 1376806 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 147
Study 1376806 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 147
Study 3920064 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Sorbinil
Number of subjects: 44
Study 3920064 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Sorbinil
Number of subjects: 44
Study 3920064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 3920064 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5 mg ophthalmic Sorbinil
Number of subjects: 44
Study 3920064 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Sorbinil
Number of subjects: 44
Study 3920064 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ophthalmic preparation
Number of subjects: 44
Study 30644784 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Management of Diabetes Mellitus type 2 (T2DM)
Number of subjects: 8
Study 29481486 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 159
Study 29481486 — intervention group
Group type: COMPARATOR
Intervention: ATV + RTV plus FTC/TDF
Number of subjects: 159
Study 27650868 — intervention group
Group type: EXPERIMENTAL
Intervention: BM32/20μg
Number of subjects: 70
Study 27650868 — intervention group
Group type: EXPERIMENTAL
Intervention: BM32/40μg
Number of subjects: 70
Study 27650868 — intervention group
Group type: EXPERIMENTAL
Intervention: BM32/10μg
Number of subjects: 70
Study 27650868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27650868 — intervention group
Group type: EXPERIMENTAL
Intervention: BM32
Number of subjects: 70
Study 24859410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision
Number of subjects: 400
Study 24859410 — intervention group
Group type: COMPARATOR
Intervention: Ligasure
Number of subjects: 400
Study 22275126 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of urinary incontinence nurse specialists in primary care
Number of subjects: 384
Study 22275126 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual by general practitioners (GPs)
Number of subjects: 384
Study 20617660 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary management breathing control therapy
Number of subjects: 50
Study 20617660 — intervention group
Group type: COMPARATOR
Intervention: Psychological information about stress
Number of subjects: 50
Study 20617660 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 50
Study 18320396 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 0
Study 18320396 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based decision aid
Number of subjects: 0
Study 18320396 — intervention group
Group type: COMPARATOR
Intervention: No pre-visit education (Control)
Number of subjects: 0
Study 18320396 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents
Number of subjects: 0
Study 18320396 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty
Number of subjects: 0
Study 18320396 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents and Faculty
Number of subjects: 0
Study 15987851 — intervention group
Group type: EXPERIMENTAL
Intervention: EBF support given pre‐, peri‐, and postnatally (IG1)
Number of subjects: 136
Study 15987851 — intervention group
Group type: EXPERIMENTAL
Intervention: EBF support given only peri‐ and postnatally (IG2)
Number of subjects: 136
Study 15987851 — intervention group
Group type: COMPARATOR
Intervention: Nonbreast‐feeding health educational support (C)
Number of subjects: 136
Study 15987851 — intervention group
Group type: EXPERIMENTAL
Intervention: IG1 and IG2 combined
Number of subjects: 136
Study 12847780 — intervention group
Group type: EXPERIMENTAL
Intervention: Millon Clinical Multiaxial Inventory‐‐Third Edition (MCMI‐III)
Number of subjects: 308
Study 10632415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐E2 (50 microg/d)
Number of subjects: 13
Study 10632415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐E2 (50 microg/d) + norethisterone acetate (250 microg/d)
Number of subjects: 13
Study 10632415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy
Number of subjects: 13
Study 8795747 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma treatment interventions (specifics not provided)
Number of subjects: 0
Study 8795747 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled trials of glaucoma treatments (specifics not provided)
Number of subjects: 0
Study 8795747 — intervention group
Group type: EXPERIMENTAL
Intervention: Current glaucoma clinical trials (specifics not provided)
Number of subjects: 0
Study 1320966 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06/1000 allicin
Number of subjects: 0
Study 1320966 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium bicarbonate
Number of subjects: 0
Study 1320966 — intervention group
Group type: EXPERIMENTAL
Intervention: Allium group (0.06/1000 allicin)
Number of subjects: 0
Study 1320966 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 3082287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin and Tegafur (group A)
Number of subjects: 0
Study 3082287 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK (group B)
Number of subjects: 0
Study 3082287 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (group C)
Number of subjects: 0
Study 3082287 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK and OK-432 (group D)
Number of subjects: 0
Study 30558918 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward-downhill treadmill training
Number of subjects: 10
Study 30558918 — intervention group
Group type: COMPARATOR
Intervention: Manual static stretching
Number of subjects: 10
Study 27974670 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score (SS)
Number of subjects: 457
Study 27974670 — intervention group
Group type: COMPARATOR
Intervention: ACEF score
Number of subjects: 457
Study 26437678 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA) in patients with ITP
Number of subjects: 11
Study 23972110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural therapy (CBT)
Number of subjects: 119
Study 23972110 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 119
Study 21410917 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer rejection
Number of subjects: 740
Study 21410917 — intervention group
Group type: COMPARATOR
Intervention: Best friend's externalizing problems
Number of subjects: 740
Study 18234488 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/d of imatinib (400mg BID)
Number of subjects: 0
Study 18234488 — intervention group
Group type: COMPARATOR
Intervention: 400 mg/d of imatinib
Number of subjects: 0
Study 16837138 — intervention group
Group type: EXPERIMENTAL
Intervention: Repithel (PVP-iodine in hydrogel, 3% concentration)
Number of subjects: 167
Study 16837138 — intervention group
Group type: COMPARATOR
Intervention: Control (Jelonet-gauze only)
Number of subjects: 167
Study 14671433 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 30
Study 10100554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) 3 g/m2
Number of subjects: 66
Study 10100554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) 4 g/m2
Number of subjects: 66
Study 10100554 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior chemotherapy regimen (1 regimen)
Number of subjects: 66
Study 10100554 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior chemotherapy regimen (>=2 regimens)
Number of subjects: 66
Study 8947399 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament deficiency
Number of subjects: 32
Study 8947399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendons-ligament augmentation device anterior cruciate ligament reconstructions
Number of subjects: 32
Study 8947399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone anterior cruciate ligament reconstructions
Number of subjects: 32
Study 8947399 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninjured subjects)
Number of subjects: 32
Study 1768562 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of indocyanine green (ICG) at 1.0 mg min‐1 for 150 min
Number of subjects: 6
Study 1768562 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propranolol (10 mg in 10 min)
Number of subjects: 6
Study 1768562 — intervention group
Group type: COMPARATOR
Intervention: Three 1-min infusions of ICG (0.5 mg kg‐1) administered at corresponding times of the day
Number of subjects: 6
Study 7091024 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% protein (HP) evening meal
Number of subjects: 8
Study 7091024 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate + 0.4% tryptophan (TRP) evening meal
Number of subjects: 8
Study 7091024 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate evening meal
Number of subjects: 8
Study 7091024 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate + TRP evening meal
Number of subjects: 8
Study 31187279 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) - 30 min at 60% VO2max
Number of subjects: 11
Study 31187279 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) - 30 min, 6 exercises, 3×10-repetition maximum
Number of subjects: 11
Study 31187279 — intervention group
Group type: COMPARATOR
Intervention: Control (Seated Rest)
Number of subjects: 11
Study 27605086 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of beta-carotene and vitamin C supplements
Number of subjects: 23
Study 25908099 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg by intravenous bolus injection
Number of subjects: 80
Study 25908099 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study 23380230 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC + HA
Number of subjects: 50
Study 23380230 — intervention group
Group type: COMPARATOR
Intervention: HA
Number of subjects: 50
Study 21944903 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane (ISF) anesthesia
Number of subjects: 45
Study 21944903 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane (SVF) anesthesia
Number of subjects: 45
Study 21944903 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol (PF) anesthesia
Number of subjects: 45
Study 19176949 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic lock solution of gentamicin (4 mg/ml) heparin (G group)
Number of subjects: 140
Study 19176949 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (H group)
Number of subjects: 140
Study 17573390 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxant (rocuronium)
Number of subjects: 300
Study 17573390 — intervention group
Group type: COMPARATOR
Intervention: No muscle relaxant
Number of subjects: 300
Study 15673992 — intervention group
Group type: EXPERIMENTAL
Intervention: n-of-1 trials
Number of subjects: 0
Study 11493411 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone (1,000 mg) and proguanil hydrochloride (400 mg) daily for 3 days
Number of subjects: 43
Study 11493411 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (1,500 mg over 3 days)
Number of subjects: 43
Study 11493411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine (75 mg) and sulfadoxine (1,500 mg) as a single dose
Number of subjects: 43
Study 9715425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg) plus amoxycillin (500 mg) twice daily for 2 weeks (LA-60 group)
Number of subjects: 76
Study 9715425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily) plus amoxycillin (500 mg twice daily for 2 weeks (LA-30 group)
Number of subjects: 76
Study 9715425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily for 6 or 8 weeks (LPZ group)
Number of subjects: 76
Study 9715425 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized-type colonization
Number of subjects: 76
Study 9715425 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-type colonization
Number of subjects: 76
Study 9715425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundic mucosal atrophy
Number of subjects: 76
Study 9715425 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanty mucosal atrophy
Number of subjects: 76
Study 7785629 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright lateral chest radiograph
Number of subjects: 100
Study 7785629 — intervention group
Group type: COMPARATOR
Intervention: Upright posteroanterior chest radiograph
Number of subjects: 100
Study 2375945 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine, 10 mg/kg
Number of subjects: 13
Study 2375945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 385096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg b.d.) for 7 days before operation
Number of subjects: 44
Study 385096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31915996 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199